Abivax Soars 15.14% on Positive Analyst Outlook

On July 16, 2025, Abivax's stock surged by 15.14% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Citizens JMP has reiterated its Market Outperform rating on Abivax, maintaining a risk-adjusted, DCF-derived price target of $33. The firm believes that Abivax is on track to report top-line results in the third quarter of 2025, which could further drive the stock's performance.

This positive outlook from Citizens JMP comes as Abivax continues to make strides in its clinical development programs, with several key trials expected to yield results in the coming months. The company's focus on innovative therapies and its strong pipeline have positioned it well within the biotech sector, attracting the interest of both institutional and retail investors.